Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:CHMA

Chiasma (CHMA) Stock Price, News & Analysis

Chiasma logo

About Chiasma Stock (NASDAQ:CHMA)

Advanced Chart

Key Stats

Today's Range
$3.76
$3.76
50-Day Range
$3.76
$4.71
52-Week Range
$2.77
$5.74
Volume
147 shs
Average Volume
2.12 million shs
Market Capitalization
$217.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CHMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chiasma and its competitors with MarketBeat's FREE daily newsletter.

CHMA Stock News Headlines

Chiasma Craters on FDA Drug Rejection
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
MPM ASSET MANAGEMENT LLC Buys - GuruFocus.com
See More Headlines

CHMA Stock Analysis - Frequently Asked Questions

Chiasma, Inc. (NASDAQ:CHMA) announced its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.18. The biotechnology company earned $1.92 million during the quarter, compared to analysts' expectations of $1.80 million.

Chiasma (CHMA) raised $76 million in an initial public offering on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Cos (BHC), Meta Platforms (META), GW Pharmaceuticals (GWPH), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX) and TherapeuticsMD (TXMD).

Company Calendar

Last Earnings
5/06/2021
Today
7/15/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CHMA
CIK
1339469
Fax
N/A
Employees
85
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$74.78 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-113.57%
Return on Assets
-57.62%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.91
Quick Ratio
7.08

Sales & Book Value

Annual Sales
$1.11 million
Price / Sales
196.11
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.59 per share
Price / Book
2.36

Miscellaneous

Outstanding Shares
57,894,000
Free Float
N/A
Market Cap
$217.68 million
Optionable
Not Optionable
Beta
1.28

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:CHMA) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners